Results 71 to 80 of about 1,440 (183)

Accelerating Pediatric Oncology Drug Development: Advances in Clinical Pharmacology, Trial Design, Non‐Clinical Evidence, and Regulatory Science

The Journal of Clinical Pharmacology, Volume 66, Issue 7, July 2026.
Abstract Pediatric oncology drug development remains uniquely challenging due to the rarity and biological heterogeneity of childhood cancers, ethical considerations in trial conduct, and the limited feasibility of large, randomized studies. Despite these barriers, recent years have seen a notable acceleration in the approval of oncology therapies for ...
Ya‐Feng Wen, Xiaoning Wang, Sarandeep Boyanapalli, Lee Anderson, Thao Dang, Guan Xing, Marianna Calvet, Tiffany Hart, Sreeneeranj Kasichayanula, Xiaochen Zhao   +9 more
wiley   +1 more source

Blastic plasmacytoid dendritic cell neoplasm and cerebral toxoplasmosis: a case report

BMC Neurology, 2022
Background The present case contributes to the limited literature on central nervous system involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Anna Maria Florescu, Anne Louise Tølbøll Sørensen, Henrik Vedel Nielsen, Daniel Tolnai, Lene Dissing Sjö, Katja Lohmann Larsen, Mohammad Al-Mahdi Al-Karagholi   +6 more
doaj   +1 more source

Radiation Therapy for Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report and Review of the Literature

Current Oncology
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive hematologic malignancy derived from plasmacytoid dendritic cells. It commonly presents as cutaneous lesions.
Masashi Taka, Shinichiro Toyoshima, Shigeyuki Takamatsu, Satoshi Kobayashi   +3 more
doaj   +1 more source

Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia

Human Vaccines & Immunotherapeutics, 2020
The IL-3 alpha chain receptor (CD123) is a cell surface protein that is widely expressed by various subtypes of acute leukemia, including acute myeloid leukemia (AML), acute lymphoblastic leukemia and blastic plasmacytoid dendritic cell neoplasm. Notably,
Ibrahim Aldoss, Mary Clark, Joo Y Song, Vinod Pullarkat   +3 more
doaj   +1 more source

18F-FDG PET/CT findings in a patient with blastic plasmacytoid dendritic cell neoplasm and post-transplant lymphoproliferative disorder after hematopoietic stem cell transplantation: a case report

Frontiers in Medicine, 2023
BackgroundBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare hematopoietic malignancy, which originating from precursors of plasmacytoid dendritic cells.
Jinzhi Chen, Xi Zhang, Linlin Ma, Yuan Gao, Zhanli Fu, Meng Liu   +5 more
doaj   +1 more source

Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis

, 2020
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive, male-biased (>3:1 M:F) hematologic malignancy in which some patients have bone marrow involvement at diagnosis (50%) and most have tumor formation in the skin (~90%), often preceding ...
Togami, Katsuhiro, Seiler, Michael, Biichle, Sabeha, Madan, Vikas, Angelot-Delletre, Fanny, Konopleva, Marina, Lane, Andrew A, Chung, Sun Sook, Louissaint, Abner, Griffin, Gabriel K, Ghandi, Mahmoud, Li, Jia, Koeffler, H. Phillip, Piccaluga, Pier Paolo, Kenyon, Christopher M., Yang, Henry, Abdel-Wahab, Omar, Lovitch, Scott B, Taylor, Justin, Kim, Sunhee, Weinstock, David M., Li, Yvonne Y., Garnache-Ottou, Francine, Morgan, Elizabeth A, Cabal-Hierro, Lucia, Pemmaraju, Naveen, Buonamici, Silvia, Hammerman, Peter S., Jardin, Fabrice   +28 more
core   +1 more source

Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data

, 2020
International audienceBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare myeloid malignancy, for which conventional chemotherapy has poor outcomes.
Beziat, Guillaume, Ysebaert, Loïc
core   +1 more source

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) arising in the setting of polycythemia vera (PV): An illustration of the emerging role of flow cytometry analysis in monitoring progression of myeloproliferative neoplasms

, 2022
This report highlights the value of flow cytometry analysis, particularly in the setting of myeloproliferative neoplasms showing features of progression, as neoplastic plasmacytoid dendritic cell (PDC) proliferations may be present, representing either a
Evans, Andrew G., Hong Fang, Wang, Wei, Siba El Hussein, John M. Bennett, Naveen Pemmaraju, Andrew G. Evans, Fang, Hong, El Hussein, Siba, Jane L. Liesveld, W. Richard Burack, Medeiros, L. Jeffrey, Bennett, John M., Sanam Loghavi, Fatima Zahra Jelloul, Loghavi, Sanam, Burack, W. Richard, Mariko Yabe, Wei Wang, L. Jeffrey Medeiros, Yabe, Mariko, Pemmaraju, Naveen, Liesveld, Jane L., Jelloul, Fatima Zahra   +23 more
core   +1 more source

Venetoclax combined with azacitidine in blastic plasmacytoid dendritic cell neoplasm: a case report and comprehensive review on the current and future treatment

Frontiers in Medicine
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare hematological malignancy with a highly aggressive behavior and median survival of <2 years. Especially, most BPDCN patients present with extensive and non-specific skin lesions,
Xiaoning Wang, Xiaoning Wang, Jiashuo Guo, Jiashuo Guo, Yan Liu, Na Zheng, Shaohan Xu, Shaohan Xu, Lianhui Wu, Ruirui Yuan, Liying Xue, Jie Li   +11 more
doaj   +1 more source

Pathology Quiz Case: Plasmacytoid Dendritic Cell Neoplasm

Allergy & Rhinology, 2014
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that possesses a heterogenous clinical and immunophenotypic presentation. The current case report describes an interesting and unique presentation of BPDCN as a primary
Quinn A. Dunlap B.S., Kristine E. Day M.D., Samuel G. Borak M.D., Bradford A. Woodworth M.D.   +3 more
doaj   +1 more source